RAD51 biomarker could complement next-generation sequencing in personalizing prostate cancer treatment
Published in Cell Reports Medicine, results of a VHIO-led study support the feasibility of using RAD51 testing to complement ...
Oncology Nurse Advisor8h
Imlunestrant Bests Standard Care in Certain Patients With ER+, HER2- Breast Cancer
The researchers found that imlunestrant prolonged progression-free survival (PFS) when compared to standard care in patients with ESR1 mutations, but there was no PFS benefit observed in the overall ...
Targeted Oncology8h
FDA Expands PATHWAY HER2 (4B5) Test to Include HER2-Ultralow Status
The PATHWAY HER2 (4B5) test is now FDA-approved to assess HER2-ultralow status in metastatic breast cancer, expanding its ...
oncnursingnews11h
T-DXd Companion Diagnostic in HER2-Ultralow Metastatic Breast Cancer Gains FDA Approval
The FDA has approved a companion diagnostic to determine if patients with HR-positive, HER2-ultralow metastatic breast cancer are eligible for T-DXd treatment.
emjreviews.com13h
Ultrafast MRI Matches Standard MRI for Breast Cancer Classification
Study finds that ultrafast MRI-based radiomics model performs just as well as standard MRI in classifying breast cancer ...